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Abstract
Background: Erectile dysfunction (ED) is highly prevalent in patients with diseases of 
cardiovascular system, including patients with atrial fibrillation (AF). Reasons for this high 
co-prevalence include endothelial dysfunction, inflammation, oxidative and emotional stress 
associated with AF. Association of AF-induced prothrombotic state and possible microthrombi 
in penile arteries with ED remains unclear. The present study aims to assess if probability of 
AF-associated risk of peripheral thromboembolism may be associated with ED in AF patients.
Methods: Probability of thromboembolic complications was assessed with two commonly used 
risk scores CHADS2 and CHA2DS2-VASc in a group of continuous AF patients. All patients 
were also asked to fill an IIEF-5 questionnaire designed for screening for ED.
Results: Mean CHADS2 score in the whole study group was 1.1 ± 1.0 points and CHA2DS2-
-VASc was 1.5 ± 1.4 points. ED was present in 57.4% of the 129-person study population. 
In patients with ED, both CHADS2 (0.9 ± 1.0 vs. 1.3 ± 1.1; p = 0.03) and CHA2DS2-VASc 
(1.2 ± 1.1 vs. 1.8 ± 1.5; p = 0.03) scores were significantly higher than in the group without 
dysfunction. After dividing the patients according to age into groups younger than 65 years 
vs. ≥ 65 years, observed correlation was no longer significant in the younger group (p > 0.05). 
In patients ≥ 65 years, in whom the risk scores are routinely used, dysfunction both CHADS2  
(1.1 ± 0.9 vs. 2.0 ± 0.9; p = 0.02) and CHA2DS2-VASc (2.3 ± 1.1 vs. 3.4 ± 1.3; p = 0.04) 
scores were higher in the group with ED.
Conclusions: Erectile dysfunctions in AF patients are associated with elevated cardioem-
bolic risk. We postulate that the diagnosis of ED should be considered an additional marker of  
prothrombotic state, and may be useful in clinical decision-making, especially in patients  
≥ 65 years old. (Cardiol J 2015; 22, 4: 446–452)
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Introduction
Erectile dysfunction (ED) is one of the most 
disabling sexual dysfunctions. It is defined as 
a consistent or recurrent inability to acquire or 
sustain an erection of sufficient rigidity and dura-
tion for sexual intercourse. In a selected population 
of men of ages ranged from 20 to 75 years, the 
overall prevalence of ED is estimated to be 16% 
but raises up to 37% in men 70–75 years of age [1]. 
These statistics are much higher in patients with 
a disease of the cardiovascular (CV) system, 
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especially associated with impaired vascular func-
tion and/or blood flow like arterial hypertension, 
atherosclerosis-related coronary and peripheral 
artery disease. Moreover, in patients with CV dis-
ease, ED is often associated with increased mortal-
ity and morbidity risk [2–5]. It has been recently 
reported that also patients with atrial fibrillation 
(AF) are at high risk of ED.
Erectile dysfunction arises as a result of con-
comitance of several components from genetic 
and anatomical dysfunctions, through the systemic 
disease to impact of lifestyle and environment. In 
many cases, a single cause of ED is not easy to 
determine, and ED is more of a result of  several 
overlapping conditions [6]. Nevertheless, in CV 
patients, a significant number of ED cases is as-
sociated with alterations of the vascular function, 
which can be associated with endothelial dysfunc-
tion, inflammation, oxidative and emotional stress 
or sympathetic activation [7–9]. Another factor 
strongly associated with ED is limitation of the 
blood flow in penile arteries caused either by 
obstruction associated with atherosclerosis or by 
microthrombi [6].
In AF patients, it was found that most of the 
previously described risk factors of the vascu-
lar dysfunction are elevated [10–12]. AF is also 
strongly associated with elevated thromboembolic 
risk. AF patients by definition are at elevated risk of 
thromboembolic stroke, deep vein thrombosis, and 
other end organs ischemia, therefore management 
and prevention of thrombosis-associated vascular 
events is one of the main treatment goals in AF 
patients [13, 14]. According to current guidelines 
assessment of thromboembolic risk and decision on 
therapeutic approach is made basing of risk score, 
mainly CHADS2 and CHA2DS2-VASc [14].
Little data is available on the potential link be-
tween elevated thromboembolic risk in AF patients 
and its impact on ED. Association of AF-induced 
prothrombotic state and possible microthrombi in 
penile arteries with ED remains unclear. Present 
study aims to assess if elevated risk of periph-
eral thromboembolism assessed by CHADS2 and 
CHA2DS2-VASc scores may be associated with ED 
in AF patients.
Methods
Study population
The study was designed as a prospective 
cross-sectional cohort study. Data were collected 
during the period from July, 2013 to July, 2014. The 
study population consisted of consecutive male 
patients aged > 18 and ≤ 70 years with a primary di-
agnosis of AF. Study patients were either electively 
hospitalized with a primary diagnosis of AF, or had 
a scheduled outpatient visit in one of the University 
Cardiology Departments participating in the study. 
AF was diagnosed based on ≥ 1 arrhythmia episode 
recorded in a 24-h electrocardiogram (ECG) Holter 
monitoring or standard 12-lead ECG in the last 
6 months. AF was classified as paroxysmal when 
it was self-terminating. Persistent AF was defined 
when an arrhythmia episode either lasted longer 
than 7 days or required termination by cardiover-
sion, and permanent AF was diagnosed when it 
was decided not to pursue rhythm control strategy. 
Due to similar clinical manifestation, persistent and 
permanent AF were analyzed as one group.
Patients were excluded from the study if they 
had: a history of prostatectomy or other procedures 
associated with a loss of sexual function, current 
use of phosphodiesterase type 5 (PDE-5) inhibi-
tors, for patients hospitalized due to AF — acute 
presentation on admission, myocardial infarction, 
stroke or decompensation of heart failure within 
6 months prior to study entry, fatal condition with 
estimated life expectancy of ≤ 6 months, general 
health status described as “frail” or “in poor gen-
eral health” by the managing physician. Physical 
examination and medical history taking were per-
formed in all the cases, and patients were assessed 
in the thromboembolic risk scores and were asked 
to fill in the ED tool described in detail below. All 
patients gave a written, informed consent prior 
to the study entry and the study protocol was ap-
proved by the University Ethics Committee.
Erectile dysfunction assessment
Erectile dysfunction was evaluated using the 
International Index of Erectile Function (IIEF) 
score. The IIEF has been described in detail 
previously. It is a self-administered questionnaire 
that provides data on ED 98% sensitivity and 88% 
specificity [15]. Patients’ responses are based on 
their experience during the last 4 weeks, and are 
scored on a 5-point scale, where lower values rep-
resent poorer sexual function. Erectile dysfunction 
was diagnosed when patient scored 25 points or 
less [16].
Thromboembolic risk assessment
The CHADS2 and CHA2DS2-VASc scores are 
widely used clinical risk scores based only on clini-
cal parameters [17, 18]. The scores were calculated 
for all patients included in the study, according to 
the scheme described below. In the CHADS2 score 
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for: history of congestive heart failure — 1 point, 
arterial hypertension — 1 point, age ≥ 75 years 
— 1 point, diabetes — 1 point, and for history 
of stroke or transient ischemic attack (TIA) — 
1 point. Diagnoses of all the diseases mentioned 
above were made based on the current diagnosis 
criteria, either as de novo diagnosis or according 
to patients’ medical records. The CHA2DS2-VASc 
scoring was as follows: heart failure — 1 point, 
arterial hypertension — 1 point, age ≥ 75 years 
— 2 points, diabetes — 1 point, history of stroke 
or TIA — 2 points, vascular disease (history of 
myocardial infarction, presence of complex aortic 
plaque, or peripheral artery disease) — 1 point, age 
65–74 years — 1 point, and female sex — 1 point. 
As the current guidelines recomend assessment 
of the thromboembolic risk only in patients > 65 
years of age, we performed an additional analysis 
for two separate groups: patients £ 65 and > 65 
years of age.
Statistical analysis
Continuous data are presented as mean 
± standard deviation (SD) and were compared 
using either the Mann-Whitney or Student’s t-test 
depending on the normal distribution, tested us-
ing the Kolmogorov-Smirnov test. Categorical 
variables are presented as the number of patients 
(percentage of the population), and their compari-
son was made using either the χ2 or Fisher’s exact 
test. A p value of less than 0.05 was considered sta-
tistically significant. All analyses were performed 
using SAS statistical software version 8.02 (SAS 
Institute, Inc., Cary, NC, USA).
Results
One hundred and twenty nine patients were 
enrolled into the study. Mean age of the study 
population was 57 years. Majority (58.9%) of pa-
tients in the study population had paroxysmal AF. 
Cardiovascular risk factors were present in many 
of the patients. Twenty-two point five percent had 
diabetes mellitus, 60.5% had arterial hypertension, 
and 18.6% were current smokers; dyslipidemia 
was diagnosed in 46.5% of patients. It translated 
into the elevated thromboembolic risk, which 
was assessed in the described risk scores. Mean 
CHADS2 score in the whole study group was 1.1 ± 
± 1.0 points and CHA2DS2-VASc was 1.5 ± 1.4 po- 
ints. Baseline characteristics of the study popula-
tion are described in Table 1.
Prevalence of the ED in the whole study 
population was high. Erectile dysfunction was di-
agnosed in 74 (57.4%) patients. Few factors were 
significantly different between the groups, and they 
are described in the Table 2. Patients with ED were 
older (60.1 ± 10.7 years) than the patients without 
the dysfunction (53.0 ± 12.0 years, p = 0.003), 
also waist circumference was higher in patients 
with the dysfunction (102.3 ± 10.4 vs. 101.7 ± 
± 15.9 cm, p < 0.0001). When we analyzed patients 
according to the history of myocardial infarction, 
there was a trend towards higher prevalence of 
history of myocardial infarction in patients (16.2% 
vs. 3.6%), but it did not reach the level of statistical 
significance (p = 0.052). In patients with ED, both 
CHADS2 (0.9 ± 1.0 vs. 1.3 ± 1.1; p = 0.03) and 
CHA2DS2-VASc (1.2 ± 1.1 vs. 1.8 ± 1.5; p = 0.03) 
scores were significantly higher than in the group 
without dysfunction (Fig. 1). We observed no dif-
ferences between the groups with and without ED 
in terms of prescribed medications, including beta-
blocker, diuretic, angiotensin converting enzyme 
inhibitors, or statins (p > 0.05).
When we divided patients in the manner de-
scribed in the guidelines, in the group younger than 
65 and ≥ 65 years of age, we observed additional 
differences described in detail in Table 3. In pa-
tients younger than 65 years, factors different 
between the groups with and without ED were: 
age (55.2 ± 7.8 vs. 50.6 ± 10.9 years; p = 0.03) 
and current smoking (32.7 vs. 32.3%; p = 0.05). In 
this group of patients, the observed association be-
tween the thromboembolic risk was not significant 
Table 1. Baseline characteristics of the study 
population.
Parameter Mean ± SD  
or n (%)
Age [years] 57.0 ± 11.8
Paroxysmal AF 76 (58.9%)
Body mass index [kg/m2] 29.3 ± 4.1
Waist circumference [cm] 102.1 ± 12.6
Systolic BP [mm Hg] 136.0 ± 16.8
Diastolic BP [mm Hg] 83.5 ± 11.8
Prior myocardial infarction 14 (10.9%)
Diabetes mellitus 29 (22.5%)
Arterial hypertension 78 (60.5%)
Smoking 24 (18.6%)
Prior stroke 8 (6.2%)
Dyslipidemia 60 (46.5%)
Family history of CVD 59 (45.7%)
SD — standard deviation; AF — atrial fibrillation; BP — blood pres-
sure; CVD — cardiovascular disease
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(1.0 ± 1.0 vs. 0.9 ± 1.0; p = 0.43, and 1.1 ± 1.1 
vs. 0.9 ± 1.0; p = 0.41), respectively for CHADS2 
and CHA2DS2-VASc (Fig. 2A).
In patients ≥ 65 years, in whom the risk 
scores are routinely used, the only factor different 
between the group with and without ED was age 
(71.2 ± 4.9 vs. 66.5 ± 1.9 years; p = 0.003) and 
the thromboembolic risk assessed in the described 
scores. In patients with ED, both CHADS2 (1.1 ± 
± 0.9 vs. 2.0 ± 0.9; p = 0.02) and CHA2DS2-VASc 
(2.3 ± 1.1 vs. 3.4 ± 1.3; p = 0.04) scores were high-
er in the group with erectile dysfunction (Fig. 2B).
Discussion
Erectile dysfunction in patients with CV dis-
ease is usually associated with coronary artery dis-
ease, cerebrovascular disease or peripheral artery 
disease. The high prevalence of ED in this group 
of patients has been extensively described and is 
associated with atherosclerotic lesions present in 
the coronary, cerebral, and peripheral, as well as 
penile arteries. Presence of the dysfunction is also 
a marker of poorer general condition and prognosis 
[19–22]. In this case, causes of high co-prevalence 
of ED with those conditions are well known, and 
the proposed pathophysiologic mechanism is 
known in the literature as the artery size hypoth-
esis [23]. According to it, because of the systemic 
nature of atherosclerosis, all major vascular beds 
are affected to the same extent. Given the differ-
ent size of the arteries supplying different vascular 
beds (i.e. heart and penis) the larger vessel would 
better tolerate the same amount of plaque com-
pared with a smaller one [23]. Therefore, ED may 
be an early sign of atherosclerotic disease, and by 
definition it should be found in majority of coronary 
artery disease patients.
In the case of AF, the pathophysiologic mecha-
nisms are completely different, and not yet fully 
understood. As it was reported previously, ED is 
also common in patients with AF, but not related 
to atherosclerosis. In our study, ED was present 
Table 2. Differences between patients with and without erectile dysfunction (ED).
Parameter Patients without  
the ED (n = 55)
Patients with  
the ED (n = 74)
P
Age [years] 53.0 ± 12.0 60.1 ± 10.7 0.003
Paroxysmal AF 37 (67.3%) 39 (52.7%) 0.11
Body mass index [kg/m2] 29.5 ± 4.4 29.1 ± 3.8 0.54
Waist circumference [cm] 101.7 ± 15.9 102.3 ± 10.4 < 0.0001
Systolic BP [mm Hg] 134.0 ± 15.6 137.4 ± 17.6 0.3
Diastolic BP [mm Hg] 81.0 ± 10.6 85.3 ± 12.3 0.08
Prior myocardial infarction 2 (3.6%) 12 (16.2%) 0.052
Diabetes mellitus 9 (16.4%) 20 (27.0%) 0.25
Arterial hypertension 29 (52.7%) 49 (66.2%) 0.21
Smoking 6 (10.9%) 18 (24.3%) 0.09
Prior stroke 6 (10.9%) 2 (2.7%) 0.11
Dyslipidemia 25 (45.5%) 35 (47.3%) 0.85
Family history of CVD 24 (43.6%) 35 (47.3%) 0.89
CHADS2 0.9 ± 1.0 1.3 ± 1.1 0.03
CHA2DS2-VASc 1.2 ± 1.1 1.8 ± 1.5 0.03
Values are mean ± standard deviation or n (%); AF — atrial fibrillation; BP — blood pressure; CVD — cardiovascular disease
Figure 1. Association between erectile dysfunction and 
CHADS2 and CHA2DS2-VASc scores in the study population.
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in 57.4% of patients. Given the relatively young 
mean age of the study population, it is a lot more 
than in the general population. Only clinical factors 
associated with higher prevalence of the dysfunc-
tion was older age and higher waist circumference 
(but not higher body mass index). The history of 
myocardial infarction was at the edge of the sta-
tistical significance, which proves that possibly 
some contribution of the high prevalence may 
be attributable to the atherosclerosis. Neverthe-
less, in majority of AF patients there were no 
obstructive lesions in the coronary arteries [24]. 
We hypothesize that high co-prevalence of AF 
and ED, besides the abovementioned endothelial 
dysfunction, inflammation, and oxidative stress, 
may be caused by microthrombi circulating in the 
blood of AF patients.
AF predisposes to hypercoagulation. The ar-
rhythmia is associated with changes in the blood 
flow in the heart chambers, which according to 
Table 3. Differences between patients with and without erectile dysfunction (ED) according to age.
Parameter Patients without the ED Patients with the ED P
Age < 65 years
Age [years] 50.6 ± 10.9 55.2 ± 7.8 0.03
Paroxysmal AF 31 (68.9%) 29 (55.8%) 0.20
Body mass index [kg/m2] 29.5 ± 4.6 29.1 ± 4.0 0.65
Waist circumference [cm] 100.6 ± 16.4 102.6 ± 9.9 0.62
Systolic BP [mm Hg] 132.5 ± 15.6 133.8 ± 16.9 0.72
Diastolic BP [mm Hg] 81.4 ± 11.3 85.8 ± 13.4 0.17
Prior myocardial infarction 1 (2.2%) 4 (7.7%) 0.45
Diabetes mellitus 7 (15.6%) 9 (17.3%) 0.97
Arterial hypertension 24 (53.3%) 30 (57.7%) 0.78
Smoking 6 (13.3%) 17 (32.7%) 0.05
Prior stroke 4 (8.9%) 2 (3.8%) 0.55
Dyslipidemia 21 (46.7%) 25 (48.1%) 0.90
Family history of CVD 21 (46.7%) 24 (46.2%) 0.96
CHADS2 0.9 ± 1.0 1.0 ± 1.0 0.43
CHA2DS2-VASc 0.9 ± 1.0 1.1 ± 1.1 0.41
Age ≥ 65 years
Age [years] 66.5 ± 1.9 71.2 ± 4.9 0.003
Paroxysmal AF 6 (60.0%) 10 (45.5%) 0.70
Body mass index [kg/m2] 29.5 ± 3.8 28.9 ± 3.6 0.70
Waist circumference [cm] 107.1 ± 10.3 101.7 ± 10.6 0.21
Systolic BP [mm Hg] 141.7 ± 14.3 144.9 ± 16.9 0.67
Diastolic BP [mm Hg] 78.9 ± 6.1 84.3 ± 10.0 0.19
Prior myocardial infarction 1 (10.0%) 8 (36.4%) 0.33
Diabetes mellitus 2 (20.0%) 11 (50.0%) 0.31
Arterial hypertension 5 (50.0% 19 (86.4%) 0.16
Smoking 0 (0.0%) 1 (4.5%) 0.68
Prior stroke 2 (20.0%) 0 (0.0%) 0.14
Dyslipidemia 4 (40.0%) 10 (45.5%) 0.73
Family history of CVD 3 (30.0%) 11 (50.0%) 0.50
CHADS2 1.1 ± 0.9 2.0 ± 0.9 0.02
CHA2DS2-VASc 2.3 ± 1.1 3.4 ± 1.3 0.04
Values are mean ± standard deviation or n (%); AF — atrial fibrillation; BP — blood pressure; CVD — cardiovascular disease
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Virchoff’s theory promote coagulation. This also 
translates into altered levels of blood coagulation 
markers like P-selectin and fibrinogen [25]. The two 
risk scores most widely used to assess the severity 
of thrombotic changes and the risk of thrombosis 
in AF patients are CHADS2 and CHA2DS2-VASc 
scores [13, 14]. Both scores showed to be predic-
tive not only of thromboembolic stroke risk, but 
also adverse vascular function, CV and total death 
in the whole AF population [26–28]. Moreover, 
a predictive value of both scores was confirmed also 
in patients with other conditions, like ischemic 
heart disease or in patients with comorbidities also 
influencing thromboembolic risk profile [29–31]. 
Their elevated values have also been shown to be 
associated with higher risk of renal damage after in-
vasive procedures [32]. All those findings are caused 
by elevated thromboembolic risk and increased 
coagulations. Even if not in all cases the thrombi 
are large enough to cause visible and/or clinically 
obvious thrombosis, the obstruction of microvessels 
and damage to end-organs. Of course, both CHADS2 
and CHA2DS2-VASc scores are not perfect and tend 
to omit some clinically important variables, with 
CHA2DS2-VASc score being more likely to identify 
patients at lower risk [33]. Nevertheless, in our 
study, both scores showed to be equally predictive.
The same mechanism may be attributable to 
the development of ED. Microthrombi forming in 
the heart and associated with AF may travel with 
the blood stream to the small-sized penile arteries 
where they cause occlusion and worsen the sexual 
function and ability to achieve and maintain an erec-
tion, and as it was previously proposed contribute 
to the development of a clinical syndrome involv-
ing AF and ED [34]. Of course, the present study 
only indirectly shows that ED is associated with 
elevated thromboembolic risk, and other further 
studies focused mainly on coagulation markers 
and/or microthrombi visualization techniques are 
necessary to prove the mentioned hypothesis. 
Nevertheless, this is the one of the first stud-
ies aiming to describe the problem of ED in AF 
patients. Moreover, it is the first to try to provide 
and explanation for its potential causes. Erectile 
dysfunction should be perceived as an important 
problem in AF patients and potentially as a re-
vealing of elevated thromboembolic risk and an 
additional indication for anticoagulation therapy, 
especially in low risk patients.
Conclusions
Erectile dysfunctions are highly prevalent 
in AF patients and are associated with elevated 
cardioembolic risk. We postulated that diagnosis 
of ED should be considered an additional marker 
of prothrombotic state, and may be useful in 
clinical decision-making, especially in patients 
≥ 65 years old.
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